ex vivo
CSL Behring to Close California R&D Site Amid Shift in Gene Therapy Strategy
CSL Behring, California R&D site closure, ex vivo gene therapy, strategic repositioning, biotech industry trends
CSL Behring Closes California R&D Site, Shifts Operations to Massachusetts Amid Strategic Repositioning
CSL Behring, California R&D site closure, gene therapy, ex vivo work, strategic repositioning, Massachusetts relocation
Bristol Myers Squibb Invests $110 Million in T-Cell Therapy Pact with Prime Medicine
Bristol Myers Squibb (BMS), Prime Medicine, T-cell therapy, Ex vivo therapies, Biotech investment, Pharmaceutical partnerships
Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus
Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration